{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T14:25:53Z","timestamp":1720621553691},"reference-count":77,"publisher":"Georg Thieme Verlag KG","issue":"S 02","funder":[{"name":"Bayer Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The vast clinical research programme for the direct, oral factor Xa inhibitor rivaroxaban has generated a wealth of data since the first rivaroxaban approval in 2008 for the prevention of venous thrombo embolism (VTE) in patients undergoing elective hip or knee replacement surgery. While rivaroxaban is widely used across a spectrum of seven indications, there is continuous commitment to investigating its wider benefits in new indications and attempts to refine current evidence. Key data from recently completed randomised controlled trials (RCTs) have shown that rivaroxaban is a feasible anticoagulation option for patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion or catheter ablation. Now, a number of Phase II and III RCTs are underway that seek to uncover further roles for rivaroxaban in patients at risk of thrombosis and aim to improve quality of life. This article will introduce and provide context for these RCTs in the contemporary management of arterial and venous thromboembolism in the following underserved areas: Patients with both NVAF and acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI); patients with embolic stroke of undetermined source (ESUS); patients who require transcatheter aortic valve replacement (TAVR); patients with acute or chronic coronary artery disease (CAD; including those with heart failure [HF]); those at risk of or suffering from cancer-associated thrombosis (CAT) and those requiring long-term anticoagulation. It is hoped that this collection of studies provides clarity around the use of rivaroxaban as a fundamental component of antithrombotic therapy in an array of clinical situations.<\/jats:p>","DOI":"10.1160\/th16-06-0484","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T08:00:54Z","timestamp":1473840054000},"page":"S2-S12","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban"],"prefix":"10.1160","volume":"116","author":[{"given":"Riccardo","family":"Cappato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"10.1160\/TH16-06-0484-1","unstructured":"Bayer Pharma AG. Xarelto Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0484-2","unstructured":"FierceBiotech. Bayer\u2019s Xarelto Approved in Canada. Available at: http:\/\/www.fiercebiotech com\/biotech\/bayer-s-xarelto-approved-canada. Accessed May 23, 2016"},{"key":"10.1160\/TH16-06-0484-3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.1160\/TH16-06-0484-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"10.1160\/TH16-06-0484-5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"10.1160\/TH16-06-0484-6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"10.1160\/TH16-06-0484-7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu367"},{"key":"10.1160\/TH16-06-0484-8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv177"},{"key":"10.1160\/TH16-06-0484-9","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000120509.64740.DC"},{"key":"10.1160\/TH16-06-0484-10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"10.1160\/TH16-06-0484-11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.025"},{"key":"10.1160\/TH16-06-0484-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.12.024"},{"key":"10.1160\/TH16-06-0484-13","unstructured":"Bayer Pharma AG. European label update of Bayer\u2019s Xarelto\u00ae now including guidance for use in patients with atrial fibrillation undergoing cardioversion (Press Release). Available at: https:\/\/www.xarelto.com\/en\/resources\/newsfeed\/european-label-update-of-bayers-xarelto-now-including-guidance-for-use-in-patients-with-atrial-fibrillation-undergoing-cardioversion. Accessed June 20, 2016"},{"key":"10.1160\/TH16-06-0484-14","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-014-9924-9"},{"key":"10.1160\/TH16-06-0484-15","unstructured":"A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy. https:\/\/ClinicalTrials.gov\/show\/NCT01729871"},{"key":"10.1160\/TH16-06-0484-16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"10.1160\/TH16-06-0484-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392303"},{"key":"10.1160\/TH16-06-0484-18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"10.1160\/TH16-06-0484-19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"10.1160\/TH16-06-0484-20","unstructured":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention. https:\/\/ClinicalTrials.gov\/show\/NCT01830543"},{"key":"10.1160\/TH16-06-0484-21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.12.006"},{"key":"10.1160\/TH16-06-0484-22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000248"},{"key":"10.1160\/TH16-06-0484-23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"10.1160\/TH16-06-0484-24","unstructured":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS). https:\/\/ClinicalTrials.gov\/show\/NCT02313909"},{"key":"10.1160\/TH16-06-0484-25","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY15M09_11"},{"key":"10.1160\/TH16-06-0484-26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.05.017"},{"key":"10.1160\/TH16-06-0484-27","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV8I1A20"},{"key":"10.1160\/TH16-06-0484-28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.54506"},{"key":"10.1160\/TH16-06-0484-29","doi-asserted-by":"crossref","unstructured":"Latib A, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv 2015; 8: pii:e001779","DOI":"10.1161\/CIRCINTERVENTIONS.114.001779"},{"key":"10.1160\/TH16-06-0484-30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509233"},{"key":"10.1160\/TH16-06-0484-31","unstructured":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes. https:\/\/ClinicalTrials.gov\/show\/NCT02556203"},{"key":"10.1160\/TH16-06-0484-32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7401.1259"},{"key":"10.1160\/TH16-06-0484-33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq326"},{"key":"10.1160\/TH16-06-0484-34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs289"},{"key":"10.1160\/TH16-06-0484-35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"10.1160\/TH16-06-0484-36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"10.1160\/TH16-06-0484-37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"10.1160\/TH16-06-0484-38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.01.004"},{"key":"10.1160\/TH16-06-0484-39","unstructured":"A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome. https:\/\/ClinicalTrials.gov\/show\/NCT02293395"},{"key":"10.1160\/TH16-06-0484-40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1197"},{"key":"10.1160\/TH16-06-0484-41","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht310.P4876"},{"key":"10.1160\/TH16-06-0484-42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr211"},{"key":"10.1160\/TH16-06-0484-43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312"},{"key":"10.1160\/TH16-06-0484-44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"10.1160\/TH16-06-0484-45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200933"},{"key":"10.1160\/TH16-06-0484-46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2006.12.037"},{"key":"10.1160\/TH16-06-0484-47","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.04.059"},{"key":"10.1160\/TH16-06-0484-48","unstructured":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease. https:\/\/ClinicalTrials.gov\/show\/NCT01776424"},{"key":"10.1160\/TH16-06-0484-49","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(98)70130-2"},{"key":"10.1160\/TH16-06-0484-50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.12.062"},{"key":"10.1160\/TH16-06-0484-51","first-page":"CD000536","volume":"6","author":"Geraghty","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1160\/TH16-06-0484-52","unstructured":"Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities. https:\/\/ClinicalTrials.gov\/show\/NCT02504216"},{"key":"10.1160\/TH16-06-0484-53","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs104"},{"key":"10.1160\/TH16-06-0484-54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.12.018"},{"key":"10.1160\/TH16-06-0484-55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.03.010"},{"key":"10.1160\/TH16-06-0484-56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202299"},{"key":"10.1160\/TH16-06-0484-57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2006.02.012"},{"key":"10.1160\/TH16-06-0484-58","unstructured":"Janssen Research & Development, LLC. Advisory Committee Briefing Document. Rivaroxaban for Reducing the Risk of Cardiovascular Events (Cardiovascular Death, Myocardial Infarction and Stroke) After Acute Coronary Syndrome (ACS). Document No.: EDMS-ERI-38428183:2.0 (April 2012). Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM304757.pdf"},{"key":"10.1160\/TH16-06-0484-59","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.266"},{"key":"10.1160\/TH16-06-0484-60","unstructured":"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure. https:\/\/ClinicalTrials.gov\/show\/NCT01877915"},{"key":"10.1160\/TH16-06-0484-61","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10516"},{"key":"10.1160\/TH16-06-0484-62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114238"},{"key":"10.1160\/TH16-06-0484-63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210384"},{"key":"10.1160\/TH16-06-0484-64","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-02-0131"},{"key":"10.1160\/TH16-06-0484-65","unstructured":"Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism). https:\/\/ClinicalTrials.gov\/show\/NCT02064439"},{"key":"10.1160\/TH16-06-0484-66","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25714"},{"key":"10.1160\/TH16-06-0484-67","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2297"},{"key":"10.1160\/TH16-06-0484-68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1118"},{"key":"10.1160\/TH16-06-0484-69","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13556"},{"key":"10.1160\/TH16-06-0484-70","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr392"},{"key":"10.1160\/TH16-06-0484-71","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu243"},{"key":"10.1160\/TH16-06-0484-72","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"10.1160\/TH16-06-0484-73","first-page":"453","volume":"8","author":"Seaman","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1160\/TH16-06-0484-74","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2303"},{"key":"10.1160\/TH16-06-0484-75","unstructured":"AWMF-Leitlinien-Register Nr. 065\/002. Available at: http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/065-002l_S2k_VTE_2016-01.pdf. Accessed February 16, 2016"},{"key":"10.1160\/TH16-06-0484-76","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70018-3"},{"key":"10.1160\/TH16-06-0484-77","unstructured":"Johnson and Johnson. New clinical research program initiated for the prevention and treatment of life-threatening blood clots in patients with cancer. Available at: http:\/\/www.jnj.com\/news\/all\/New-Clinical-Research-Program-Initiated-for-the-Prevention-and-Treatment-of-Life-Threatening-Blood-Clots-in-Patients-with-Cancer. Accessed May 23, 2016"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH16-06-0484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T14:32:10Z","timestamp":1521556330000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH16-06-0484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":77,"journal-issue":{"issue":"S 02","published-online":{"date-parts":[[2017,12,15]]},"published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1160\/th16-06-0484","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}